Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

BUY
$0.36 - $0.75 $8,203 - $17,091
22,788 New
22,788 $10,000
Q1 2023

May 12, 2023

SELL
$1.39 - $2.26 $3,569 - $5,803
-2,568 Reduced 57.64%
1,887 $2,000
Q4 2022

Feb 08, 2023

BUY
$1.32 - $69.2 $553 - $28,994
419 Added 10.38%
4,455 $6,000
Q3 2022

Nov 10, 2022

BUY
$3.18 - $66.0 $5,952 - $123,552
1,872 Added 86.51%
4,036 $13,000
Q2 2022

Aug 10, 2022

SELL
$2.83 - $4.02 $2,779 - $3,947
-982 Reduced 31.21%
2,164 $8,000
Q1 2022

May 16, 2022

SELL
$2.99 - $4.17 $304 - $425
-102 Reduced 3.14%
3,146 $12,000
Q4 2021

Feb 14, 2022

BUY
$3.77 - $5.24 $9,206 - $12,796
2,442 Added 302.98%
3,248 $12,000
Q3 2021

Nov 15, 2021

SELL
$5.13 - $6.78 $16,887 - $22,319
-3,292 Reduced 80.33%
806 $4,000
Q2 2021

Aug 13, 2021

BUY
$5.13 - $7.63 $20,684 - $30,764
4,032 Added 6109.09%
4,098 $27,000
Q1 2021

May 12, 2021

SELL
$3.63 - $11.77 $2,061 - $6,685
-568 Reduced 89.59%
66 $0
Q4 2020

Feb 11, 2021

SELL
$3.21 - $5.26 $5,739 - $9,404
-1,788 Reduced 73.82%
634 $2,000
Q3 2020

Nov 12, 2020

BUY
$3.85 - $5.5 $6,706 - $9,581
1,742 Added 256.18%
2,422 $10,000
Q2 2020

Jul 31, 2020

SELL
$4.15 - $6.04 $5,880 - $8,558
-1,417 Reduced 67.57%
680 $3,000
Q1 2020

May 01, 2020

BUY
$3.07 - $8.26 $6,437 - $17,321
2,097 New
2,097 $9,000
Q4 2019

Feb 14, 2020

SELL
$6.97 - $12.3 $1,554 - $2,742
-223 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$9.45 - $17.17 $14,912 - $27,094
-1,578 Reduced 87.62%
223 $2,000
Q2 2019

Aug 14, 2019

BUY
$12.52 - $20.81 $2,979 - $4,952
238 Added 15.23%
1,801 $24,000
Q1 2019

May 14, 2019

BUY
$1.81 - $38.86 $2,829 - $60,738
1,563 New
1,563 $32,000

About BIO-PATH HOLDINGS INC


  • Ticker BPTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 7,160,160
  • Market Cap $7.73M
  • Description
  • Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the...
More about BPTH
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.